Cdmo Recognized Point In Time was Scinai Immunotherapeutics’s largest revenue line in fiscal 2025, bringing in $1.81M of $2.62M (69%).
| Timing of Transfer of Good or Service | FY 2025 |
|---|---|
| Cdmo Recognized Point In Time | $1.81M |
| Cdmo Recognized Over Time | $812.00K |
| Total | $2.62M |
Scinai Immunotherapeutics brought in $2.62M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. Cdmo Recognized Point In Time was the largest at $1.81M (69.0%), ahead of Cdmo Recognized Over Time at $812.00K (31.0%).
Scinai Immunotherapeutics (SCNI) reports its revenue by timing of transfer of good or service. In fiscal 2025, Cdmo Recognized Point In Time was its largest revenue line, bringing in $1.81M (69.0% of the total), followed by Cdmo Recognized Over Time at $812.00K (31.0%).
Cdmo Recognized Point In Time was Scinai Immunotherapeutics' largest revenue line in fiscal 2025, bringing in $1.81M, or 69.0% of the $2.62M total across its two revenue lines.
Every figure comes from Scinai Immunotherapeutics' annual financial filings, as reported. Each line keeps the name Scinai Immunotherapeutics gives it, and years follow its fiscal calendar.
Scinai Immunotherapeutics' revenue by timing of transfer of good or service goes back to fiscal 2025, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.